BEIJING, SHANGHAI and BOSTON, December 8, 2024 — Jacobio Pharma (1167.HK), a clinical-stage oncology company specializing in developing therapies targeting previously undruggable targets, today announced preliminary Phase I data for its BET inhibitor, JAB-8263, in the treatment of myelofibrosis (MF) at the 2024 ASH (American Society of Hematology) Annual Meeting in San Diego, California. 

The data indicated that JAB-8263 was well-tolerated, with a Recommended Phase 2 Dose (RP2D) established at 0.3mg once daily. Preliminary efficacy data for JAB-8263 monotherapy in MF patients were encouraging, showing spleen volume reduction (SVR) and total symptom score (TSS) improvements in most participants.

As of the data cutoff on October 17, 2024, the study included 16 patients with intermediate-/high-risk MF, with 13 patients completing at least one post-treatment efficacy assessment.

• All patients exhibited a mean SVR of -19.95% at week 24 and -26.16% at best response.
• Two patients achieved an SVR of ≥35%, with one patient showing an SVR of -34.9%.
• Sixty percent (6/10) of patients experienced a ≥50% reduction in TSS at week 24.
• Among the eight patients previously treated with JAK inhibitors, two showed best response SVRs of -41.2% and -34.9%, respectively.
• At week 24, fifty percent (3/6) of patients previously treated with JAK inhibitors achieved a TSS reduction of ≥50% (TSS50).

Expansion of the JAB-8263 monotherapy trial in MF and solid tumors is underway. Andrea Wang-Gillam, M.D., Ph.D., Chief Medical Officer and Global Head of R&D at Jacobio, commented, “These initial findings showcase the potential clinical benefit of our potent BET inhibitor in MF. We will continue to investigate the potential of JAB-8263 across a wider range of indications, aiming to offer new hope to more cancer patients.”

About Jacobio

Jacobio Pharma (1167.HK) is dedicated to developing and delivering innovative products and solutions. Our research focuses on novel molecular targets across six key signaling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB, and MYC. Our goal is to establish our key projects among the world’s top three. We aspire to become a global leader in drug R&D, collaborating with partners worldwide. Jacobio’s R&D centers are located in Beijing, Shanghai, and Boston, utilizing our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.

 

SOURCE Jacobio Pharma

“`